Soumyadeep Bhaumick (HIFA country representative India and member of HIFA Evidence-Informed Policy and Practice working group [https://www.hifa.org/support/members/soumyadeep]) has published a blog today on his website.
He draws attetion to the latest India AIIMS/ICMR 2021 COVID guideline
which describes chloroquine as a “may do” in its 'Clinical Guidance for Management of Adult COVID-19 patients'.
As Soumyadeep points out: 'Evidence from randomized controlled trial shows that hydroxychloroquine does do not have any effect on mortality (based on data from 10859 patients ; 29 studies) in COVID=19 patients . In fact patients given hydroxychloroquine may have significantly more diarrhea, nausea and vomiting compared to those not given so. Diarrhoea and vomiting are known to increase the risk of hypovolaemia, hypotension and acute kidney injury, additional health systems burdens which one should avoided at all costs in this phase of the pandemic... the use of hydroxychloroquine does not make any sense – it increases the number of people who need mechanical ventilation(based on data from 6379 patients ;5 studies)... It is high time that issues in the guideline development process that has been already identified are resolved such that lives of patients can be saved through evidence informed therapies.'